One pill to replace three? diabetes combo drug tested
NCT ID NCT07333742
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a single pill containing three diabetes medicines (gemigliptin, dapagliflozin, and metformin) works the same in the body as taking them separately. Fifty healthy adults took either the combo pill or the separate drugs after a meal, and researchers measured drug levels in their blood. The goal was to see if the combo pill is a good alternative for simplifying diabetes treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemigliptin, Dapagliflozin, Metformin
What this could lead to
If successful, this could allow people with type 2 diabetes to take one pill instead of multiple, simplifying their treatment.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. It only checks how the drugs are absorbed, not if they work better or are safer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea